EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

NCT06802835 | Recruiting Phase 1 DMC

• 1 other identifier: EGFR+PD-1+Chemo for r/mNPC
• Study Type: interventional
• Target: 148
• Locations: 1 country
• Sites: 1

Brief Summary

This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.

Conditions

Nasopharyngeal Cancinoma (NPC); Recurrent Nasopharynx Carcinoma; Metastatic Nasopharyngeal Carcinoma

Keywords

EGFR antibody; PD-1 antibody; chemotherapy

Outcome Measures

Primary Outcomes (1)

• Progression-free survival (PFS)

  From the date of recruiting to the first occurrence of disease progression as determined according to RECIST v1.1 or death from any cause, whichever occurs first.

  1 year

Secondary Outcomes (5)

• Adverse events

  Up to 16 months

• Overall survival (OS)

  1 year

• Objective response rate (ORR)

  1 year

• Disease control rate (DCR)

  1 year

• Quality of life (QoL)

  1 year

Study Arms (1)

EGFR+PD-1+Chemo

EXPERIMENTAL

Drug: EGFR Antibody; Drug: PD-1 antibody; Drug: Gemcitabine, Cisplatin; Radiation: IMRT

Interventions

EGFR Antibody DRUG

6 cycles for combined therapy. Maintenance for 1 year.

EGFR+PD-1+Chemo

PD-1 antibody DRUG

6 cycles for combined therapy. Maintenance for 1 year.

EGFR+PD-1+Chemo

Gemcitabine, Cisplatin DRUG

6 cycles for combined therapy.

EGFR+PD-1+Chemo

IMRT RADIATION

IMRT for primary lesion

EGFR+PD-1+Chemo

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with nasopharyngeal carcinoma who have recurred/metastasized after initial treatment or radical treatment;
• Age 18-75, male or female;
• Pathological diagnosis of nasopharyngeal carcinoma;
• ECOG score 0-1;
• Have not previously received any anti-tumor therapy such as radiotherapy, chemotherapy, immunotherapy or biotherapy for recurrence/metastasis;
• No contraindications of chemotherapy, immunotherapy and targeted therapy;
• At least 1 measurable lesion that meets RECIST 1.1 criteria;
• Blood routine examination standards should meet: WBC≥3.0×109/L, ANC≥1.5×109/L, PLT≥100×109/L, HGB≥90g/L (no blood transfusion and blood products within 14 days, no G-CSF and other hematopoietic stimulating factors are used to correct);
• Biochemical tests should meet the following criteria: TBIL≤2.0×ULN, ALT, AST≤2.5×ULN, BUN and CRE≤1.5×ULN or endogenous creatinine clearance ≥60ml/min (Cockcroft-Gault formula);
• Good coagulation function: defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN; If the subject is receiving anticoagulant therapy, as long as PT is within the intended range of anticoagulant drug use;
• The myocardial enzyme spectra were in the normal range;
• Women of childbearing age must already be using reliable contraception or have had a pregnancy test (serum or urine) within 7 days of enrollment with a negative result and be willing to use an effective method of contraception during the trial and for 3 months after the last anti-PD-1 antibody administration. For male subjects whose partners are women of reproductive age, effective contraception should be used during the trial and within 3 months after the last anti-PD-1 antibody administration;
• The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up;

You may not qualify if:

• Patients with recurrence who can be treated with local resection or radiotherapy;
• Known to be allergic to the investigational drug or any excipients thereof, or has had a severe allergic reaction to other monoclonal antibodies;
• Patients have symptoms of central nervous system metastasis such as brain edema and need hormonal intervention;
• Had an active infection or unexplained fever \>38.5℃ during screening or prior to the first dose (the investigator determined that the subject's fever due to the tumor could be enrolled);
• Have any active autoimmune disease or history of autoimmune disease (e.g., interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism \[may be included after normal hormone replacement therapy\]); Patients with vitiligo or complete remission of asthma in childhood without any intervention as adults could be included, but patients with asthma requiring medical intervention with bronchodilators could not be included;
• Have congenital or acquired immunodeficiency (such as HIV), active hepatitis B (HBV-DNA≥103 copy number /ml), or hepatitis C (hepatitis C antibody positive and HCR-RNA above the lower detection limit of analytical methods);
• Previous or co-existing uncured malignancies, except cured basal cell carcinoma of the skin, carcinoma in situ of the cervix and superficial bladder cancer;
• Uncontrolled cardiovascular disease: Grade II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms); Patients with grade III-IV cardiac insufficiency according to NYHA standards, or left ventricular ejection fraction (LVEF) \<50% indicated by cardiac color ultrasound; Myocardial infarction within 1 year;
• If the subject has undergone major surgery, the toxic effects and/or complications of the surgical intervention must be fully recovered before treatment is initiated;
• Within 4 weeks prior to the first use of the investigational drug (participants in the follow-up period are counted as the last use of the investigational drug or device) or are currently participating in another clinical study;
• Live vaccine received within 4 weeks prior to the first administration of the investigational drug is allowed to receive inactivated virus vaccine for seasonal influenza by injection, but not live attenuated influenza vaccine for nasal administration;
• Pregnant or lactating women;
• In the investigator's judgment, the subjects had other factors that might have led to their forced discontinuation of the study, such as other serious medical conditions (including mental illness) requiring concomitant treatment, serious abnormalities in laboratory test values, or family or social factors that might have affected the safety of the subjects or the circumstances of the trial data collection.

Sponsors & Collaborators

• Sun Yat-sen University: lead

Study Sites (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

RECRUITING

MeSH Terms

Conditions

Nasopharyngeal Neoplasms; Nasopharyngeal Carcinoma

Interventions

spartalizumab; Gemcitabine; Cisplatin

Condition Hierarchy (Ancestors)

Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Neoplasms by Site; Neoplasms; Nasopharyngeal Diseases; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type

Intervention Hierarchy (Ancestors)

Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds

Central Study Contacts

Zhao Chong PhD.

CONTACT

139022061610; zhaochong@sysucc.org.cn

Miao Jingjing MD.

CONTACT

13631355201; miaojj@sysucc.org.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof.

Study Record Dates

• First Submitted: January 25, 2025
• First Posted: January 31, 2025
• Study Start: May 1, 2025
• Primary Completion (Estimated): February 20, 2027
• Study Completion (Estimated): February 20, 2029
• Last Updated: May 16, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)